Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2019-07-03
Target enrollment:
Participant gender:
Summary
To evaluate the preliminary efficacy of the established dose of indoximod in combination with
immune checkpoint inhibition as measured by the best overall response rate (ORR) (complete
response (CR) + partial response (PR))across both standard of care agents administered
sequentially in patients with unresectable stage III or stage IV melanoma